Uncategorized
Avedro Announces Agreement with the FDA for the First U.S. Pivotal Phase 3 Trial of an Epi-on Cross-Linking Treatment for Patients with Progressive Keratoconus
WALTHAM, Mass.--(BUSINESS WIRE)--#clinicaltrials--Avedro Announces Agreement with FDA for First U.S. Pivotal Phase 3 Trial of Epi-On Cross-Linking Treatment for Patients with Progressive Keratoconus.